Plain-English translation of NCT07226219 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Children with sickle cell disease often have trouble with attention, memory, and focus—problems that can affect school performance and quality of life. This trial is testing whether methylphenidate, a medication already used safely in other children with attention problems, can help improve these skills in children with sickle cell disease. The study will give the medication to 30 children for 4 weeks and carefully track how well it works and whether it is safe.
Although this medication is known to help with attention and focus in other groups of children, it has rarely been studied in children with sickle cell disease. Researchers want to understand whether this treatment could help this group of children do better in school and feel better overall.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would take the medication once a day for 4 weeks. The first dose would be given at the clinic, and then you would take it at home. A parent or caregiver would help track whether you are taking the medication each week by doing a brief video check-in. You would also complete some simple tests and answer questions about how you are feeling and whether the medication is helping—at the start of the study, right after you start the medication, and then weekly during the 4 weeks.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States